
    
      A non-randomized prospective clinical interventional study which includes 45 non previously
      treated patients with DME. The patients received a single intravitreal injection of 2.5 mg
      bevacizumab. Follow-up included clinical examination (best corrected visual acuity (BCVA,
      intraocular pressure (IOP), cataract grading, DME characteristics and systemic check-up)
      pre-injection, at first visit, at weeks 1 and 2 and months 1 and 3. OCT and fluorescein
      angiography was evaluated at months 1 and 3.
    
  